New app and urine test aim to boost HIV med adherence in men who use stimulants

NCT ID NCT07125235

First seen Jan 08, 2026 · Last updated Jun 22, 2026 · Updated 37 times

Summary

This study tests a program called reSTART for men living with HIV who also use stimulants. It combines a smartphone app, a urine test to check medication levels, and motivational messages to help them remember to take their HIV drugs. The goal is to see if this approach can lower their viral load and reduce stimulant use. About 270 men are being recruited for this trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEHAVIORAL INTERVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mobile health app and urine tenofovir self-test

What this could lead to

If successful, this could provide a practical tool to help men with HIV and stimulant use stay on their medication and achieve viral suppression.

What could go wrong

This is a relatively small, early-stage trial (270 participants) focused on a specific group, so results may not apply broadly. The intervention relies on self-monitoring, which may not work for everyone.

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.